Department of Neurology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine, Université de Montréal, Montréal, QC, Canada.
Can J Neurol Sci. 2022 Jul;49(4):595-597. doi: 10.1017/cjn.2021.151. Epub 2021 Jun 29.
We present five cases of pediatric drug-resistant epilepsy (DRE) that failed management using high cannabidiol (CBD) doses, but had significant reduction in seizure frequency with reintroduction or increasing doses of tetrahydrocannabinol (THC). There is growing evidence supporting the use of whole-plant CBD-rich extracts (containing THC and other cannabinoids) in the treatment of pediatric DRE. Based on our experiences and reports in the literature, we propose that, in patients who fail management with an initial trial of high-dose CBD-focused therapy, there may be a role for add-on THC-focused formulations.
我们报告了 5 例儿科耐药性癫痫（DRE）病例，这些病例使用高剂量大麻二酚（CBD）治疗未能得到有效控制，但重新引入或增加四氢大麻酚（THC）剂量后，癫痫发作频率显著降低。越来越多的证据支持使用富含大麻二酚的全植物提取物（含有 THC 和其他大麻素）治疗儿科 DRE。根据我们的经验和文献报告，我们提出，在初始高剂量 CBD 治疗试验失败的患者中，添加 THC 为重点的配方可能有一定作用。
